ABBREVIATED UNAUDITED ACCOUNTS

FOR THE YEAR ENDED 30 APRIL 2016

FOR

MOLECULAR ONCOLOGY LIMITED

MOLECULAR ONCOLOGY LIMITED (REGISTERED NUMBER: 08483710)

CONTENTS OF THE ABBREVIATED ACCOUNTS for the year ended 30 April 2016

	Page
Company Information	1
Abbreviated Balance Sheet	2
Notes to the Abbreviated Accounts	3

MOLECULAR ONCOLOGY LIMITED

COMPANY INFORMATION for the year ended 30 April 2016

DIRECTOR: Dr R C Swanton Dr B T Cloke **SECRETARY: REGISTERED OFFICE:** 7 Lindisfarne Road Wimbledon London SW20 ONW **REGISTERED NUMBER:** 08483710 (England and Wales) **ACCOUNTANTS:** Sandison Lang & Co 2 St Marys Road Tonbridge Kent TN9 2LB

MOLECULAR ONCOLOGY LIMITED (REGISTERED NUMBER: 08483710)

ABBREVIATED BALANCE SHEET 30 April 2016

	Notes	2016 £	2015 £
CURRENT ASSETS Cash at bank		75,440	133,381
CREDITORS Amounts falling due within one year NET CURRENT ASSETS TOTAL ASSETS LESS CURRENT LIABILITIES		(34,038) 41,402 41,402	(26,110) 107,271 107,271
CAPITAL AND RESERVES Called up share capital Profit and loss account SHAREHOLDERS' FUNDS	2	$ \begin{array}{r} 19 \\ \underline{41,383} \\ \underline{41,402} \end{array} $	19

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2016.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2016 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of
- (b) each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The abbreviated accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the director on 18 October 2016 and were signed by:

Dr R C Swanton - Director

MOLECULAR ONCOLOGY LIMITED (REGISTERED NUMBER: 08483710)

NOTES TO THE ABBREVIATED ACCOUNTS

for the year ended 30 April 2016

1. ACCOUNTING POLICIES

Accounting convention

The financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective January 2015).

Turnover

Turnover represents net invoiced sales of services, excluding value added tax.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

2. CALLED UP SHARE CAPITAL

Allotted,		

Number:	Class:	Nominal	2016	2015
		value:	£	£
19	Ordinary	1	<u>19</u>	19

3. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 30 April 2016 and 30 April 2015:

	2016	2015
	£	£
Dr R C Swanton		
Balance outstanding at start of year	(1,309)	36,279
Amounts advanced	-	32,250
Amounts repaid	(4,931)	(69,838)
Balance outstanding at end of year	<u>(6,240)</u>	(1,309)

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.